dbl™ bortezomib
pfizer new zealand limited - bortezomib 3mg (as a mannitol boronic ester) - powder for injection - 3 mg - active: bortezomib 3mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
hospira™ bortezomib
pfizer new zealand limited - bortezomib 3mg (as a mannitol boronic ester) - powder for injection - 3 mg - active: bortezomib 3mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
bortezomib for injection powder for solution
pfizer canada ulc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3mg - bortezomib (bortezomib mannitol boronic ester) 3mg - antineoplastic agents
bortezomib rowex 3.5 mg powder for solution for injection
rowex ltd - bortezomib (as mannitol boronic ester) - powder for solution for injection - 3.5 milligram(s) - bortezomib
bortezomib teva 3.5 mg powder for solution for injection
teva b.v. - bortezomib (as mannitol boronic ester) - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib
bortezomib s.k. 3.5 mg
k.s.kim international (sk- pharma) ltd., israel - bortezomib as mannitol boronic ester - powder for solution for injection - bortezomib as mannitol boronic ester 3.5 mg - bortezomib - multiple myelomabortezomib s.k is indicated for the treatment of patients with multiple myeloma.mantle cell lymphomabortezomib s.k is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.bortezomib s.k in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
taro-bortezomib powder for solution
taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents
taro-bortezomib powder for solution
taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 2.5mg - bortezomib (bortezomib mannitol boronic ester) 2.5mg - antineoplastic agents
taro-bortezomib powder for solution
taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 1mg - bortezomib (bortezomib mannitol boronic ester) 1mg - antineoplastic agents
bortezomib for injection powder for solution
teva canada limited - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents